Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nelfinavir and SBRT for Oligometastases
NCT01728779Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jan 2014
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nelfinavir in oligometastatic disease (OMD), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Jan 2014; status: completed.
02
Drugs
nelfinavir
03
Conditions
oligometastatic disease (OMD)
Beyond the preview
Go deeper on NCT01728779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01728779.